CytomX Therapeutics (CTMX) Q2 2024 earnings summary

Executive summary

• Advanced clinical pipeline with CX-904 (EGFR/CD3 T-cell engager), CX-2051 (EpCAM ADC), and CX-801 (masked IFNα2b), all in early clinical development and progressing through phase 1 studies.

• Positive initial phase 1A data for CX-904, especially in pancreatic cancer, with 33% partial response in efficacy-evaluable PDAC patients and favorable safety profile; phase 1b update expected by end of 2024.

• CX-2051 and CX-801 both initiated phase 1 studies in 2024, with CX-2051 focused on colorectal cancer and initial data expected in H1 2025; CX-801 initial data anticipated in H2 2025.

• Over 15 active research collaborations and major partnerships with Amgen, Astellas, BMS, Regeneron, and Moderna; $10M in preclinical milestones achieved from Astellas in 2024.

• Chris Ogden promoted to Chief Financial Officer in 2024.

Financial highlights

• Q2 2024 revenue was $25.1M, up from $24.7M in Q2 2023, driven by collaboration milestones and partnerships.

• Net loss for Q2 2024 was $6.5M (EPS: $(0.08)), compared to $1.1M loss (EPS: $(0.02)) in Q2 2023.

• Cash, cash equivalents, and investments totaled $137.2M as of June 30, 2024, down from $150.3M at March 31, 2024.

• Operating expenses for Q2 2024 were $33.6M; R&D expenses rose to $25.2M, and G&A expenses increased to $8.4M.

• Deferred revenue decreased to $160.5M from $212.3M at year-end, reflecting recognition of upfront and milestone payments.

Outlook and guidance

• Existing capital resources expected to fund operations through the end of 2025, excluding future milestones or new business development.

• CX-904 phase 1b update anticipated by year-end 2024; initial phase 1 data for CX-2051 expected in H1 2025 and for CX-801 in H2 2025.

• Additional fundraising may be required beyond 2025, depending on development progress and market conditions.

• Revenue expected to fluctuate based on collaboration milestones and research progress.